100% of Patients On IMX-110 Completed Planned Treatment Cycles Immix Biopharma, Inc. (NASDAQ:IMMX) 100% of patients treated with IMX-110 completed...
CBT is the first of several rare cannabinoid launches planned for the first half of 2022; includes CBDV and THCVExpands...
BOSTON, Jan. 19, 2022 (GLOBE NEWSWIRE) -- Yumanity Therapeutics (Nasdaq: YMTX), a clinical-stage biopharmaceutical company focused on the discovery and development...
Vivos Also Announces Improved Pricing Agreement With SleepImage Dentists and Patients Report Exceptional User Experience with SleepImage Home Sleep Test...
London, UK and New York, US, 19 January 2022 COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated...
NEW HAVEN, Conn., Jan. 19, 2022 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial...
VANCOUVER, British Columbia, Jan. 19, 2022 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB:...
Latest Appointment Continues Build-Out of Leadership Team for San Diego OperationsSAN DIEGO and GAINESVILLE, Ga., Jan. 19, 2022 (GLOBE NEWSWIRE)...
Fourth Quarter 2021 Preliminary Unaudited Total Revenues of Approximately $26 Million, the Highest Quarterly Revenue for the Company Since Inception...
TORONTO, Jan. 19, 2022 (GLOBE NEWSWIRE) -- VitalHub Corp. (the “Company”) (TSX: VHI) is pleased to announce the 5-year licensing...
PetVivo Holdings, Inc. John Lai PetVivo Holdings, Inc. invites individual and institutional investors as well as advisors and analysts, to...
- Dr. Gandara, Professor and Senior Advisor to the Thoracic Oncology Program at University of California Davis, brings deep expertise...
-- Fourth Quarter 2021 net sales for UPNEEQ grew by approximately 41% to $3.1 million compared to the third quarter...
SPARTA, N.J., Jan. 19, 2022 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or the “Company”), is a commercial-stage...
This news release constitutes a “designated news release” for the purposes of the Company’s prospectus supplement dated May 11, 2021...
CARLSBAD, Calif., Jan. 19, 2022 (GLOBE NEWSWIRE) -- Acutus Medical, Inc. (“Acutus” or the “Company”) (Nasdaq: AFIB), an arrhythmia management...
COPENHAGEN, Denmark, January 19, 2022 – Bavarian Nordic A/S (OMX: BAVA) announced today the appointment of Russell Thirsk as Executive...
Results of European study potentially incorporated into U.S. regulatory strategy for FDA approval Opportunity for ColoAlert to become the gold...
Second positive Phase 3 Dupixent® (dupilumab) trial confirms significant improvements for patients with prurigo nodularis Dupixent is the first and...
REGULATED INFORMATION Recruitment for ALLOB tibial facture Phase IIb study ongoing and on schedule to release topline data in Q1...
